By Caroline Valetkevitch
NEW YORK (Reuters) - U.S. stocks climbed on Thursday as energy shares bounced with oil prices, while news PFIZER (PFE.NY)would buy Hospira in a massive deal also lifted investor sentiment.
Adding to the upbeat tone, weekly jobless claims rose less than expected last week. The report comes on the heels of a private payrolls report that fell short of expectations on Wednesday and ahead of a monthly employment report on Friday.
Oil prices bounced from the prior session's selloff, with U.S. crude
"Anytime you have M&A it's always positive for the market, and of course you have oil prices rebounding," said Peter Cardillo, chief market economist at Rockwell Global Capital in New York. "From a technical perspective, the market has been doing pretty good, and the earnings season is winding down ... and in general it wasn't all that bad."
Pfizer
The Dow Jones industrial average <.DJI> rose 152.33 points, or 0.86 percent, to 17,825.35, the S&P 500 <.SPX> gained 15.45 points, or 0.76 percent, to 2,056.96 and the Nasdaq Composite <.IXIC> added 30.11 points, or 0.64 percent, to 4,746.81.
The S&P 500 has been volatile recently due to swings in crude prices and developments in Greek debt negotiations. Greece said on Thursday it would not be "blackmailed" by its European Union partners but it wanted to find a joint solution to its debt and austerity crisis.
Other data showed the U.S. trade deficit in December widened to its highest since 2012, which could damp down the fourth-quarter growth estimate, and nonfarm productivity fell more than expected in the fourth quarter.
Michael Kors
Advancing issues outnumbered declining ones on the NYSE by 2,162 to 823, for a 2.63-to-1 ratio; on the Nasdaq, 1,880 issues rose and 784 fell, a 2.40-to-1 ratio.
The S&P 500 was posting 38 new 52-week highs and 2 lows; the Nasdaq Composite was recording 76 new highs and 28 lows.
(Editing by Bernadette Baum and Nick Zieminski)
Relacionados
- Pfizer acuerda comprar la firma Hospira por unos 17.000 millones de dólares
- Pfizer comprará Hospira por 15.000 mln dlr para impulsar su negocio de copias y genéricos
- EEUU.- Pfizer compra el proveedor de fármacos inyectables y tecnologías de infusión Hospira por 14.898 millones
- Pfizer compra el proveedor de fármacos inyectables y tecnologías de infusión Hospira por 14.898 millones
- Economía.- Pfizer compra el proveedor de fármacos inyectables y tecnologías de infusión Hospira por 14.898 millones